+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sustained effectiveness of osmotic-release methylphenidate: a study of 266 cases



Sustained effectiveness of osmotic-release methylphenidate: a study of 266 cases



Revista de Neurologia 48(7): 339-345



Methylphenidate (MTF) is effective for the treatment of attention deficit/hiperactivity disorder (ADHD). Osmotic-release MTF (MTF-O) allows a sustained effect along the day on attention and behaviour in patient with ADHD with a single dose. To confirm the sustained effectiveness of the MTF-O from the clinical point of view, in the family circle: Study of 266 patients with ADHD. They were aged between 5 and 17 years. Distribution for sex 3/1 (boys/girls). Treatment with MTF-O was added and retired in two successive weekends, alternating the days. During these four days the following scales were filled at different hours: quantified criteria of DSM-IV-TR, modified ICG-M, and translated and modified Depremb-R. The following finds were observed under treatment: a statistically significant decrease in inattention, hyperactivity and impulsiveness (p < 0.01); a clinical improvement when getting up and going to bed by means of Depremb-R scale (p < 0.01); a reduction of the symptomatic intensity in the criteria of DSM-IV-TR, in the morning and in the afternoon (p < 0.01); a global improvement in attention and behaviour when getting up, lunchtime, dinner, and before going to bed according to the modified ICG-M. MTF-O improves characteristic symptoms of ADHD from the first hours of the morning until the hour of going to bed according to family assessment.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 056047974

Download citation: RISBibTeXText

PMID: 19319813


Related references

Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?. Pharmacoeconomics 33(5): 489-509, 2016

Relative efficacy of long acting stimulants on children with attention deficit hyperactivity disorder a comparison of standard methylphenidate sustained release methylphenidate sustained release dextro amphetamine and pemoline. Pediatrics 86(2): 226-237, 1990

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry and Clinical Neurosciences 63(2): 167-175, 2009

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Current Medical Research and Opinion 27(Suppl. 2): 35-44, 2012

Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology 30(5): 554-564, 2011

Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. Plos One 10(5): E0127237, 2016

No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder. Clinical Neuropharmacology 40(1): 11-15, 2016

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Canadian Journal of Clinical Pharmacology 13(1): E50-E62, 2006

Galactorrhea Probably Related with Switching from Osmotic-release Oral System Methylphenidate (MPH) to Modified-release MPH: An Adolescent Case. Clinical Psychopharmacology and Neuroscience 15(3): 282-284, 2017

Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Experimental and Clinical Psychopharmacology 6(4): 367-374, 1998

The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharmaceutics and Drug Disposition 10(2): 165-171, 1989

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. Cns Drugs 22(2): 157-170, 2008

Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder. European Review for Medical and Pharmacological Sciences 17(17): 2345-2349, 2013

Sustained Release Methylphenidate. Child Psychology and Psychiatry Review 5(3): 108-113, 2000

Sustained-release methylphenidate. Medical Letter on Drugs and Therapeutics 26(673): 97-98, 1984